<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's disease</z:e> leads to intermittent non-hemolytic <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> by a reduction of hepatic <z:chebi fb="0" ids="16990">bilirubin</z:chebi> glucuronidation associated with the presence of the <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase (UGT) 1A1*28 polymorphism </plain></SENT>
<SENT sid="1" pm="."><plain>It is considered benign because it does not result in hepatocellular damage </plain></SENT>
<SENT sid="2" pm="."><plain>However, pharmacogenetic analyses have linked UGT1A1*28 to drug toxicity and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> predisposition </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="0" ids="37670">protease inhibitor</z:chebi> <z:chebi fb="0" ids="37924">atazanavir</z:chebi> (ATV) is an inhibitor of hepatic UGT activity leading to <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in individual patients </plain></SENT>
<SENT sid="4" pm="."><plain>Whether this is linked specifically to UGT1A1*28 or to more complex variants influencing glucuronidation is unclear </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred and six ATV-treated patients were characterized and genotyped for UGT1A1*28, the UGT1A3 (-66C) and UGT1A7 (-57G) promoter variants, and UGT1A7(129K/131K) </plain></SENT>
<SENT sid="6" pm="."><plain>ATV treatment increased median <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels from 10 to 41 micromol/L (P = .001) with <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> exceeding 43 micromol/L in 37% </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002904'>Hyperbilirubinemia</z:hpo> over 43 micromol/L was significantly associated not only with UGT1A1*28 but also with UGT1A3-66C, UGT1A7-57G, and UGT1A7(129K/131K), although these variants do not naturally occur in linkage dysequilibrium in blood donors </plain></SENT>
<SENT sid="8" pm="."><plain>Homozygous combinations of UGT1A1*28 with the other variants increased from 7.4% (<z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to 42 micromol/L) to 41% to 46.1% (43 to &gt;85 micromol/L), and 100% (&gt;85 micromol/L) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> six patients with <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> greater than 85 micromol/L were homozygous for <z:hpo ids='HP_0000001'>all</z:hpo> four variants identifying a haplotype inherited on a single allele </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, the genetic variant associated with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's disease</z:e> is identified as part of a haplotype of four UGT1A variants spanning three genes at the UGT1A gene locus </plain></SENT>
<SENT sid="11" pm="."><plain>This haplotype predisposes to <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in ATV treatment and may have an additional role as a pharmacogenomic risk factor for drug therapy </plain></SENT>
</text></document>